Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Front Med (Lausanne) ; 11: 1390803, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39091293

RESUMO

Objective: Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cancer and currently lacks effective biomarkers. This research aims to analyze and identify RNA editing profile associated with ccRCC prognosis through bioinformatics and in vitro experiments. Methods: Transcriptome data and clinical information for ccRCC were retrieved from the TCGA database, and RNA editing files were obtained from the Synapse database. Prognostic models were screened, developed, and assessed using consistency index analysis and independent prognostic analysis, etc. Internal validation models were also constructed for further evaluation. Differential genes were investigated using GO, KEGG, and GSEA enrichment analyses. Furthermore, qPCR was performed to determine gene expression in human renal tubular epithelial cells HK-2 and ccRCC cells A-498, 786-O, and Caki-2. Results: An RNA editing-based risk score, that effectively distinguishes between high and low-risk populations, has been identified. It includes CHD3| chr17:7815229, MYO19| chr17:34853704, OIP5-AS1| chr15:41590962, MRI1| chr19:13883962, GBP4| chr1:89649327, APOL1| chr22:36662830, FCF1| chr14:75203040 edited sites or genes and could serve as an independent prognostic factor for ccRCC patients. qPCR results showed significant up-regulation of CHD3, MYO19, MRI1, APOL1, and FCF1 in A-498, 786-O, and Caki-2 cells, while the expression of OIP5-AS1 and GBP4 was significantly down-regulated. Conclusion: RNA editing site-based prognostic models are valuable in differentiating between high and low-risk populations. The seven identified RNA editing sites may be utilized as potential biomarkers for ccRCC.

2.
J Int Med Res ; 52(8): 3000605241274563, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-39188141

RESUMO

OBJECTIVE: Identifying precise biomarkers for colorectal cancer (CRC) detection and management remains challenging. Here, we developed an innovative prognostic model for CRC using cuproptosis-related long non-coding RNAs (lncRNAs). METHODS: In this retrospective study, CRC patient transcriptomic and clinical data were sourced from The Cancer Genome Atlas database. Cuproptosis-related lncRNAs were identified and used to develop a prognostic model, which helped categorize patients into high- and low-risk groups. The model was validated through survival analysis, risk curves, independent prognostic analysis, receiver operating characteristic curve analysis, decision curves, and nomograms. In addition, we performed various immune-related analyses. LncRNA expression levels were examined in normal human colorectal epithelial cells (FHC) and CRC cells (HCT-116) using quantitative polymerase chain reaction (qPCR). RESULTS: Six cuproptosis-related lncRNAs were identified: ZKSCAN2-DT, AL161729.4, AC016394.1, AC007128.2, AL137782.1, and AC099850.3. The prognostic model distinguished between high-/low-risk populations, demonstrating excellent predictive ability for survival outcomes. Immunocorrelation analysis showed significant differences in immune cell infiltration and functions, immune checkpoint expression, and m6A methylation-related genes. The qPCR results showed significant upregulation of ZKSCAN2-DT, AL161729.4, AC016394.1, AC007128.2 in HCT-116 cells, while AL137782.1 and AC099850.3 expression patterns were significantly downregulated. CONCLUSION: Cuproptosis-related lncRNAs can potentially serve as reliable diagnostic and prognostic biomarkers for CRC.


Assuntos
Biomarcadores Tumorais , Neoplasias Colorretais , Biologia Computacional , Regulação Neoplásica da Expressão Gênica , RNA Longo não Codificante , Humanos , RNA Longo não Codificante/genética , Neoplasias Colorretais/genética , Neoplasias Colorretais/patologia , Neoplasias Colorretais/diagnóstico , Neoplasias Colorretais/mortalidade , Biologia Computacional/métodos , Biomarcadores Tumorais/genética , Prognóstico , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Retrospectivos , Células HCT116 , Curva ROC , Nomogramas , Idoso , Perfilação da Expressão Gênica , Análise de Sobrevida
3.
Birth Defects Res ; 116(5): e2350, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38761027

RESUMO

BACKGROUND: Cyprodinil is a widely used fungicide with broad-spectrum activity, but it has been associated with cardiac abnormalities. (-)-Epicatechin gallate (ECG), a natural polyphenolic compound, has been shown to possess protective properties in cardiac development. METHODS: In this study, we investigated whether ECG could mitigate cyprodinil-induced heart defects using zebrafish embryos as a model. Zebrafish embryos were exposed to cyprodinil with or without ECG. RESULTS: Our results demonstrated that ECG significantly improved the survival rate, embryo movement, and hatching delay induced by cyprodinil. Furthermore, ECG effectively ameliorated cyprodinil-induced cardiac developmental toxicity, including pericardial anomaly and impairment of cardiac function. Mechanistically, ECG attenuated the cyprodinil-induced alterations in mRNA expression related to cardiac development, such as amhc, vmhc, tbx5, and gata4, as well as calcium ion channels, such as ncx1h, atp2a2a, and cdh2. Additionally, ECG was found to inhibit the activity of the aryl hydrocarbon receptor (AhR) signaling pathways induced by cyprodinil. CONCLUSIONS: In conclusion, our findings provide evidence for the protective effects of ECG against cyprodinil-induced cardiac developmental toxicity, mediated through the inhibition of AhR activity. These findings contribute to a better understanding of the regulatory mechanisms and safe utilization of pesticide, such as cyprodinil.


Assuntos
Catequina , Coração , Receptores de Hidrocarboneto Arílico , Peixe-Zebra , Animais , Receptores de Hidrocarboneto Arílico/metabolismo , Coração/efeitos dos fármacos , Catequina/análogos & derivados , Catequina/farmacologia , Cardiopatias Congênitas/metabolismo , Embrião não Mamífero/efeitos dos fármacos , Embrião não Mamífero/metabolismo , Transdução de Sinais/efeitos dos fármacos , Fungicidas Industriais/farmacologia , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos
4.
Pak J Pharm Sci ; 28(1 Suppl): 415-20, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25631518

RESUMO

This paper aims to discuss the initial clinical effect of treating bone defect of long bone osteomyelitis with Masquelet technology. A retrospective analysis was made among the recruited 25 patients with long bone osteomyelitis patients from April, 2013 to February 2014 from Henan Provincial People's Hospital. Clinical effect of treating long bone osteomyelitis with Masquelet technology and the possible effects of vancomycin in different doses on knitting were also evaluated in follow-up visit lasting for 6~18 months, and 22 cases' bone was healed on imaging at the last follow up. According to Samantha X ray score criteria, Samantha score of regular dose group and high dose group in 4 months after operation was 4.16 and 3.09, respectively. There were 12 cases in regular-dose antibiotic group, among which, 1 case had delayed wound healing, and 3 cases reoccurred; there were 10 cases in high-dose antibiotic group, among which, no cases reoccurred after operation. Masquelet technology is a reliable and easy osteomyelitis treatment. Notably, it shows significant advantages for long bone reconstruction induced by infection and trauma. Bone cement with high dose of vancomycin has better effect on controlling osteomyelitis than bone cement with regular dose of vancomycin.


Assuntos
Osso e Ossos/cirurgia , Mieloma Múltiplo/complicações , Osteomielite/cirurgia , Procedimentos de Cirurgia Plástica , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Vancomicina/uso terapêutico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA